In the archives of the Dutch royal family there is a hitherto unknown report of a childbirth by the Leiden court physician Prof. H.D. Gaubius, in which he provides a detailed description, in French, of the first, prolonged and unfortunate parturition, in 1769, of Wilhelmina of Prussia, the wife of the hereditary stadholder Willem V. There was apparently a discrepancy between the presenting head and the size of the birth canal. Initially, an expectant policy was followed in the hope that the natural course of events would prevail, but ultimately and after due consideration it was decided to terminate the expulsion by means of a Van Roonhuysen lever, the vectis; this procedure was carried out by the Amsterdam obstetrician Albertus Titsingh. It turned out that the infant had died during delivery. Following the spontaneous delivery of the placenta, the puerperium proceeded without complications.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
Am Heart J
February 2019
Heart and Vascular Center, Semmelweis University, H-1122 Városmajor str 68, Budapest, Hungary.
Background: CSL112 (apolipoprotein A-I [human]) is a plasma-derived apolipoprotein A-I developed for early reduction of cardiovascular risk following an acute myocardial infarction (AMI). The safety of CSL112 among AMI subjects with moderate, stage 3 chronic kidney disease (CKD) is unknown.
Methods: CSL112_2001, a multicenter, placebo-controlled, parallel-group, double-blind, randomized phase 2 trial, enrolled patients with moderate CKD within 7 days following AMI.
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
Circulation
December 2016
From PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical, Harvard Medical School, Boston, MA (C.M.G., S.K., Y.D., M.Y., P.J.); Duke Clinical Research Institute, Cardiovascular Division, Department of Medicine, Duke University Health, Durham, NC (P.T., J.H.A.); INSERM-Unité 1148, France Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, France Université Paris-Diderot, Sorbonne- Paris Cité, France National Heart and Lung Institute, Paris, France (P.G.S.); Imperial College London, UK Institute of Cardiovascular Medicine and Science, and Royal Brompton Hospital, London, UK (P.G.S.); Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH (A.M.L.); Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands (J.J.P.K.); Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York (R.M.); CSL Behring, LLC, King of Prussia, PA (D.M.D., L.I.D.); Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Department of Cardiology, Warsaw Medical University, Warsaw, Poland (M.Z.); Department of Cardiology, Canisius Wilhelmina Ziekenhuis, Nijmegen, the Netherlands (T.O.O.); and Department of Medicine, Stanford University, Stanford, CA (R.A.H.).
Background: Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies. CSL112 is an infusible, plasma-derived apoA-I that has been studied in normal subjects or those with stable coronary artery disease. This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 in patients with a recent acute myocardial infarction.
View Article and Find Full Text PDFRationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.
Am Heart J
October 2016
Department of Medicine, Stanford University, Stanford, CA.
Background: Despite aggressive pharmacotherapy and stenting, there is a residual risk of major adverse cardiovascular events among patients with acute coronary syndrome. High-density lipoprotein (HDL) has been a major target for secondary acute coronary syndrome prevention; however, a better understanding of the physiologic function of HDL has demonstrated that a high cholesterol efflux capacity, rather than high HDL concentrations alone, may be critical to improving outcomes. CSL112, a reconstituted, infusible human apolipoprotein A-I, has been demonstrated to increase cholesterol efflux capacity and to have a protective effect in experimental models of atherosclerotic cardiovascular disease.
View Article and Find Full Text PDF[Comfort after a sad outcome of pregnancy. Two letters of Frederick the Great to Wilhelmina of Prussia].
Ned Tijdschr Geneeskd
February 2010
Verloskunde en Gynaecologie aan de Universiteit van Amsterdam, Amsterdam, The Netherlands.
After her unfortunate experience of parturition Princess Wilhelmina of Prussia, married to stadhouder Prince Willem V, received two letters of comfort from her beloved godfather King Frederick II (Frederick the Great) of Prussia. These letters illustrate the special close connection there was between them. The letters also give a view on the difficult question of giving comfort after perinatal death.
View Article and Find Full Text PDF[Gaubius' description of the first parturition of Wilhelmina of Prussia in 1769; 'The unlucky birth of the princess mijne gemaelinne'].
Ned Tijdschr Geneeskd
March 2004
Universiteit van Amsterdam, Peppinghof 3, 1391 BA Abcoude.
In the archives of the Dutch royal family there is a hitherto unknown report of a childbirth by the Leiden court physician Prof. H.D.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!